

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - FADED TEXT
 - ILLEGIBLE TEXT
 - SKEWED/SLANTED IMAGES
 - COLORED PHOTOS
 - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
 - GRAY SCALE DOCUMENTS
-

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C08L 3/00	A1	(11) International Publication Number: WO 92/14781 (43) International Publication Date: 3 September 1992 (03.09.92)
(21) International Application Number: PCT/US91/07557 (22) International Filing Date: 22 October 1991 (22.10.91) (30) Priority data: 658,659 21 February 1991 (21.02.91) US (71) Applicant: UNIVERSITY OF SOUTH ALABAMA [US/US]; Administration Building, Rm. 131, Mobile, AL 36688 (US). (72) Inventor: SIKES, C., Steven ; 253 Chidester Street, Mobile, AL 36607 (US). (74) Agents: KELBER, Steven, B. et al.; Oblon, Spivak, McClelland, Maier & Neustadt, Crystal Square Five - Fourth Floor, 1755 South Jefferson Davis Highway, Arlington, VA 22202 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: POLYAMINO ACID DISPERSANTS (57) Abstract <p>Polyamino acids of the formulae (I): poly (X)_n poly (Y)_m and (II). In formula (I) each X independently is aspartic acid, glutamic acid, phosphoserine, phosphohomoserine, phosphotyrosine, or phosphothreonine, each Y independently is alanine, leucine, isoleucine, valine, glycine or other non polar, amino acid residues, n is 2 to 60, m is 2 to 60, and n + m is ≥ 5, and wherein poly (X)_n may contain up to 10 % of the Y residues and poly (Y)_m may contain up to 10 % of the X residues, and salts thereof; and in formula (II): poly (X')_a poly (Y')_b each X' independently is aspartate, glutamate, glutamine, asparagine, or anionic derivatives of these amino acids, or phosphoserine, each Y' independently is a phosphorylated amino acid such as phosphoserine, phosphohomoserine, phosphotyrosine, phosphothreonine, phosphoglutamine, phosphoasparagine or mixtures of these residues, a is 2 to 150, b is 1 to 3, and a + b is ≥ 5, and salts of these peptides; are effective as dispersing agents for minerals in aqueous media and for stabilizing aqueous suspensions of minerals.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

DescriptionPolyamino Acid DispersantsTechnical Field

The present invention relates to a method for
5 dispersing mineral particles by using polyamino acids as
dispersing agents. This includes mineral dispersions in
aqueous media, detergent compositions for dispersion of
soil particles, dispersion of pigments in cosmetics and
paints, and dispersion of minerals in making paper.

10 Background Art

Dispersions of particles in aqueous and other media
are important in many applications; e.g., paints,
detergents, cosmetics, and paper. In addition, methods for
dispersing mineral particles in aqueous media are important
15 for the prevention of corrosion and scaling of cooling and
boiler equipment. Particular problems may arise when the
aqueous sample contains more than one kind of mineral
particle.

The importance of keeping minerals dispersed in
20 aqueous media has led to much work in this area, and the
use of polymers as dispersing agents has been explored.
Thus, Bendiksen and Parsons, Proceedings of ACS Division of
Polymeric Materials, Vol. 57, pp. 719-725, (1987) disclose
the use of sulfonic acid/acrylic acid copolymers and
25 poly(acrylic acid) as dispersing agents for clay and iron
oxide. Masler et al., Corrosion 88, paper no. 11, NACE
(1988) disclose the use of various acrylic acid copolymers
and sulfonated styrene copolymers as dispersing agents for
calcium phosphonate. Smyk et al., Corrosion 88, paper no.
30 14, NACE (1988) disclose the use of various terpolymers
which contain monomers derived from acrylic acid as

dispersing agents for a variety of minerals. Hoots et al., Corrosion 89, paper no. 175, NACE (1989) discuss the mechanisms by which conventional dispersing agents disperse minerals in aqueous media. U.S. Patent No. 3,839,215
5 discloses the use of poly- α -hydroxyacrylic acid in detergents to sequester metal ions.

The use of polymers based on amino acids as dispersing agents has also been studied. U.S. Patent No. 4,640,943 discloses the use of polyaspartic acid and polyglutamic
10 acid as surface modifiers for improving the wettability and enhancing the dispersibility of inorganic fillers. German Patent Application DE 37 24 460 discloses the use of polyglutamic acid and polyaspartic acid and their salts as
15 cleansing and detergent compositions.

U.S. Patent Nos. 4,428,749 and 4,732,693 disclose the use of polyaspartic acid as an antiredeposition agent in detergent compositions.

Japanese Patent Application Kokai 59-209635 discloses
20 the use of wetting agents which contain polyglutamic acid in shampoos and rinses in hair or skin lotions and in solid or liquid detergents.

U.S. Patent No. 3,846,380 discloses the use of
25 terminal group derivatized polyaspartic acid and derivatives of polyaspartic acid which may be enriched in polyaspartic acid for use as foaming agents, solubilizing agents, dispersing agents, emulsifying agents, rust-proofing agents, fibertreating agents, level dying agents, and retarding agents.

Chemical Abstract Vol. 79, 55246 broadly discloses the use of poly(amino acids) as surfactants in detergents in cosmetics. In particular, the use of polyaspartic acid and polyaspartic acid derivatives as surfactants is disclosed.

- 5 German Patent Application DE 36 26 672 discloses the use of polyaspartic acid amide and its salt derivatives as a scale remover.

- U.S. Patent No. 4,363,797 discloses the use of polyaspartic acid derivatives which may contain free
10 polyaspartic acid units as a component in shampoos and rinsing lotions.

Japanese Patent Application Kokai 50-38520 discloses photographic compositions which contain polyglutamic acid derivatives and pigment powders.

- 15 Japanese Patent Application Kokai 63-28890 discloses the use of polyamino carboxylic acids for the removal of carbonate scale from a geothermal power generation plant.

Disclosure of the Invention

- Accordingly, one object of the present invention is to
20 provide dispersing agents for stabilizing aqueous dispersions of minerals.

It is another object of the present invention to provide a method for stabilizing aqueous mineral dispersions.

- 25 It is another object of the present invention to provide stabilized aqueous mineral dispersions.

It is another object of the present invention to provide stable dispersions of minerals in aqueous media which contain a dispersing agent based on polyamino acids.

It is another object of the present invention to
5 provide deterative systems which contain such dispersing agents.

It is another object of the present invention to provide cosmetics which contain such dispersing agents.

These and other objects, which will become apparent
10 during the course of the following detailed description, have been achieved by the Inventor's discovery that polyamino acids of the formulae (I) and (II):

Poly (X)_n poly (Y)_m (I)

where each X independently is aspartic acid, glutamic
15 acid, phosphoserine, phosphohomoserine, phosphotyrosine, or phosphothreonine, each Y independently is alanine, leucine, isoleucine, valine, glycine or other nonpolar, amino acid residues,

20 n is 2 to 60,

m is 2 to 60, and

n + m is ≥ 5 ,

and wherein poly (X)_n may contain up to 10% of the Y
residues and poly (Y)_m may contain up to 10% of the X
25 residues, and salts thereof; and

poly (X')_a Poly (Y')_b (II)

where each X' independently is aspartate, glutamate,
glutamine, asparagine, or anionic
derivatives of these amino acids, or
phosphoserine,

5

each Y' independently is a phosphorylated amino acid
such as phosphoserine, phosphohomoserine,
phosphotyrosine, phosphothreonine,
phosphoglutamine, phosphoasparagine or
mixtures of these residues,

10

a is 2 to 150,

b is 1 to 3, and

a + b is ≥ 5 , and

salts of these peptides; are effective as dispersing
agents for minerals in aqueous media and for stabilizing
aqueous suspensions of minerals.

15

Brief Description of the Drawings

A more complete appreciation of the invention and many
of the attendant advantages thereof will be readily
obtained as the same become better understood by reference
to the following detailed description when considered in
connection with the accompanying drawings, wherein:

20

Figure 1 illustrates the measurement of dispersion of
kaolin (control, +, polyasp, - Δ -);

Figures 2 and 3 illustrate the efficacy of various dispersing agents for stabilizing an aqueous dispersion of iron oxide which also contains calcium. Figure 2:

- HO-ASP₂₀-Ala₈-NH₂, 1 µg/ml, •; HO-ASP₃₀-Ala₈-NH₂, 1 µ/ml, ▲;
5 HO-ASP₂₀-Ala₂₀-NH₂, 1 µg/ml, Δ; and thermal polyasp, 1 µg/ml, O. Figure 3: Asp₂₀-Ala₈, ▲; industrial terpolymer, +; polyaspartate, Δ; and polyacrylate, +.

- Figure 4 illustrates the efficacy of various dispersing agents for stabilizing an aqueous dispersion of
10 iron oxide in which calcium is not present, polyacrylate, +; polyaspartate, Δ; terpolymer, +; and ASP₂₀Ala₈, ▲; and

Figure 5 illustrates the measurement of stabilizing an aqueous dispersion of calcium hydroxyapatite, control, +; and thermal polyasp, ▲.

15 Best Mode for Carrying Out the Invention

Thus, the general structure of the polypeptides of the present invention may be represented by formulae (I) and (II):



- 20 where each X independently is aspartic acid, glutamic acid, phosphoserine, phosphohomoserine, phosphotyrosine, or phosphothreonine,

- each Y independently is alanine, leucine, isoleucine, valine, glycine or other nonpolar, amino acid
25 residues

n is 2 to 60, preferably 15-50, more preferably 30-50,

m is 2 to 60, preferably 3-15, more preferably 4-10,

n + m is ≥ 5 , preferably n + m is 15-80, more preferably

15-40,

5 and wherein poly (X)_n may contain up to 10% of the Y residues and poly (Y)_m may contain up to 10% of the X residues and salts thereof.

poly (X')_a poly (Y')_b (II)

10 where each X' independently is aspartate, glutamate, glutamine, asparagine, or anionic derivatives of these amino acids, or phosphoserine,

each Y' independently is a phosphorylated amino acid
such as phosphoserine, phosphohomoserine,
15 phosphotyrosine, phosphothreonine, phosphoglutamine, phosphoasparagine or mixtures of these residues, a is 2 to 150,

b is 1 to 3, and

a + b is ≥ 5 , and


20 salts of these peptides, particularly those with physiologically acceptable anions and cations.

As can be seen from the general formula (I), the anionic amino acids in the polypeptides of formula (I) are clustered on one end of the amino acid chain, whereas the nonpolar amino acids are clustered on the other end. Thus,

these polypeptides are not random copolymers. In the formula (I), the X amino acids may either be at the C-terminus or the N-terminus. In other words, the aspartic acid, glutamic acid, etc., residues may be segregated at
5 the N-terminus or the C-terminus.

The X amino acids may be entirely comprised of any one of the X group, or may be any combination of members of the group. Similarly, the Y amino acids may be entirely any one of the Y group, or may be any combination of members of
10 the group. For example, poly (X) could be made up entirely of phosphorylated amino acids.





Peptides wherein up to 10% of the X (anionic) residues are replaced by Y (non-polar) residues and vice versa are also within the scope of this invention. To illustrate
15 this possibility, the following peptide is considered.



The Y residues are ten alanines. One of these residues (10%) could be replaced by an anionic residue (e.g., aspartic acid or glutamic acid). Similarly, the X residues
20 are ten aspartic acid residues. One of these could be replaced by a non-polar amino acid (e.g., alanine, glycine, valine, etc.). Naturally, only integral numbers of replacement amino acids are possible.

Specific preferred examples of formulas of poly-
25 peptides of formula (I) are the following:





wherein:

$n = 10-60$, preferably $15-50$.

$m = 2-10$, preferably $3-8$.





10 $x = 2-5$, preferably $2-3$.

[pSer = phosphoserine; that is, serine which has been phosphorylated on the side chain hydroxyl].

In each of the above formulas, some or all of the alanine residues may be replaced by other nonpolar amino acids, such as leucine, isoleucine, valine and glycine. Similarly, some or all of the aspartic acid residues may be replaced by other anionic amino acids such as glutamic acid, and vice versa. Further, some of the glutamic acid residues or aspartic acid residues may be replaced by phosphoserine, phosphohomoserine, phosphotyrosine, phosphothreonine or other phosphorylated amino acids. Generally, amino acids containing a free hydroxyl group can be phosphorylated on the hydroxyl group. The phosphoserines

could also be phosphohomoserine, phosphotyrosine, or phosphothreonine.

Some specific preferred embodiments of the polypeptide of formula (I) are the following compounds:









As can be seen from the above description of the
10 compounds of formula (I), a large number of polypeptides fall within the scope of the present invention. However, each of them has in common the structural feature of clustered hydrophobic or nonpolar amino acids on one end of the polypeptide and clustered anionic amino acids on the
15 other end of the polypeptide. They are also generally small polypeptides having from 10-80 amino acid residues, preferably 10-60 amino acid residues, most preferably 20-50 amino acid residues.

In the above formula (II), both X' and Y' may be
20 phosphoserine, so that polyphosphoserine molecules are included. However, preferably, if X' is phosphoserine, Y' is other than phosphoserine. In another preferred embodiment, X' is aspartate or glutamate, particularly preferably aspartate. Y' is particularly preferably
25 phosphoserine.

By anionic derivatives of the amino acids of X', it is meant that the amino acid (i.e. aspartate, glutamate, asparagine, or glutamine) is phosphorylated, sulfated, phosphonated or sulfonated. Preferably, the side chain of the amino acid is treated with an appropriate reagent to result in one or more (e.g. 1-3), preferably one, phosphate, sulfate, phosphonate, or sulfonate moiety. If the α -amino group of the peptide is available for reaction, it may also be phosphorylated, sulfated, phosphonated or sulfonated. These derivatives can be prepared by the transamidation reaction of Fong and Kowalski, U.S. Patent No. 4,678,840 (1987), which is incorporated herein by reference.

The Y' residue may be a phosphorylated amino acid selected from the following group:



The number of Y' amino acids, b, is preferably 2-3, particularly preferably 2.

The number of X' residues, a, is preferably 10-50, particularly preferably 15-45, most preferably 30-40.

The sum of a + b is preferably greater than or equal to 5, particularly preferably greater than or equal to 10.

5 The maximum of a + b is 153.

The chemical connections between the X' residues, the Y' residues and the X'-Y' residues is generally an amide bond, connected by way of the alpha amino and carboxyl groups of two amino acids. However, it is also within the
10 scope of the present invention to have bonds between the alpha amino group of one amino acid and the beta carboxyl group of an aspartate residue, or between the alpha amino group of one amino acid and the gamma carboxyl group of a glutamic acid residue. These types of bonds may also occur
15 in the compounds of formula (I).

The X, Y, X', and Y' amino acid residues will generally be L-amino acids. However, it is also possible for the X, Y, X', and/or Y' residues to be D-amino acids, or the peptide/polypeptide molecule may be made up of a
20 combination of D and L residues, such as a racemic mixture.

The X' residues may be connected to the Y' residues by way of a carboxyl group of an X' residue and an amino group of a Y' residue (C-terminus X' residue), or between a carboxyl group of a Y' residue and an amino group of an X'
25 residue (N-terminus X' residue).

Particularly preferred subgenera of compounds and species, of formula (II) are shown herein below:

H-(pSer)₁-(Asp)₁₅₋₄₅-OH, preferably

H-(pSer)₁-(Asp)₄₀-OH

H-(pSer)₂-(Asp)₁₅₋₄₅-OH, preferably

H-(pSer)₂-(Asp)₄₀-OH

5 H-(pSer)₁-(pTyr)₁₅₋₄₅-OH, preferably

H-(pSer)₁-(pTyr)₄₀-OH

H-(Asp)₁₅₋₄₀-(pSer)₁-OH, preferably

H-(Asp)₄₀-(pSer)₁-OH

10 H-(Asp,Glu)₁₅₋₄₅-(pSer)₁-OH (aspartate, glutamate
copolymer)

H-(pSer)₁-(Asp,Glu)₁₅₋₄₅-OH

etc. (e.g., salts, mixed salts). The abbreviations used
herein are defined as follows:

	pSer	: phosphoserine
15	Asp	: aspartate, aspartic acid
	Glu	: glutamate, glutamic acid
	Tyr	: tyrosine
	pTyr	: phosphotyrosine

pHomoser : phosphohomoserine

pThr : phosphothreonine

pGln : phosphoglutamine

pAsn : phosphoasparagine

5 The acidic side chains of the amino acid residues making up the present molecules may be in protonated form or may be in a salt form, or a mixture thereof. For example, the aspartate residues may be protonated so that they are aspartic acid residues, and the glutamate residues
10 may be protonated so that they are glutamic acid residues. Similarly, the anionic derivatives of the amino acids may be in anionic form (e.g. sulfate, phosphonate, sulfonate), or may be protonated.

Salts of any of the acidic residues set forth above in
15 either formula (I) or (II), especially the sodium and potassium salts, are also within the scope of this invention. When phosphorylated amino acids are incorporated in the compounds, they may be present as salts, e.g., Ca^{+2} , Mg^{+2} , di-Na^{+} , di-K^{+} , and the like. Salts may also be with
20 transition metals such as zinc, aluminum, nickel and copper, preferably zinc and aluminum. Further, salts of the amino group, such as the p-toluenesulfonate, acetate, etc. are also contemplated.

With respect to the salt forms of the above-identified
25 molecules, it is to be noted that the zinc and aluminum salts may be preferred, since it is known that zinc and aluminum salts of other molecules can inhibit mineral deposition. For example, U.S. Patent 4,522,806 (1985) by

H.R. Muhlemann and I.P. Sayer mentions oral compositions and zinc salts. In addition, U.S. Patents 4,100,269 (1978) and 4,152,418 (1979) deal with zinc and tartar-control toothpaste.

5 The cations that seem to be the best mineralization inhibitors are Zn^{2+} and Al^{3+} ; however, others such as Mg^{2+} , Cu^{2+} , and Ni^{2+} have been studied and also appear to be useful. Accordingly, it is contemplated that the present invention is not limited to specific salts mentioned
10 herein, and that other cationic metal salts of the present peptides, particularly cationic transition metal salts, could be formed and used for the purposes described herein.

 It is also possible, and within the scope of the present invention, to have physical combinations of
15 conventional dispersing agents and one or more of the present compounds. Such compositions may exert a synergistic effect in terms of dispersion stabilization, as is the case for crystallization inhibitors as described in Sikes and Wheeler, CHEMTECH, October 1988, 620-626.

20 The polyamino acids of formulae (I) and (II) may be prepared as described in U.S. Patent No. 4,868,287 and U.S. Patent Application Serial No. 07/339,672 filed April 18, 1989, which are incorporated herein by reference.

 Thus, compounds of formulae (I) and (II) may be
25 synthesized by any number of techniques now available for synthesis of simple and complex low molecular weight polypeptides. Generally speaking, these techniques involve stepwise synthesis by successive additions of amino acids to produce progressively larger molecules. The amino acids
30 are linked together by condensation between the carboxyl

group of one amino acid and the amino group of another amino acid to form a peptide bond. To control these reactions, it is necessary to block the amino group of one amino acid and the carboxyl group of the other. The
5 blocking groups should be selected for easy removal without adversely affecting the polypeptides, either by racemization or by hydrolysis of formed peptide bonds. Certain amino acids have additional functional groups such as the carboxyl groups of aspartic acid and glutamic acid
10 and the hydroxyl groups of serine, homoserine and tyrosine. It is usually necessary to block these additional groups with an easily removed blocking agent, so that they do not interfere with the desired condensation for the formation of peptide bonds.

15 A wide variety of procedures exist for the synthesis of polypeptides, and a wide variety of blocking agents have also been devised. Most of these procedures are applicable to the peptides of the present invention. The preferred method for synthesis of the peptides of formulae (I) and
20 (II) is a solid-phase technique. In this procedure, an amino acid is bound to a resin particle, and the peptide is generated in a stepwise manner by successive additions of protected amino acids to the growing chain. The general procedure is well known, and has been described in many
25 articles, for example: Merrifield, R.B., J. Am. Chem. Soc. 96, 2986-2993, 1964.

In one aspect of the present invention, the compounds of formulae (I) and (II) may be used to stabilize a mineral dispersion. Thus, the present invention relates to a
30 method of stabilizing an aqueous mineral dispersion comprising adding a compound of formula (I) or (II) to said dispersion. The present invention also relates to

stabilized aqueous mineral dispersions containing a mineral and a compound of formula (I) or (II).

In the present method and dispersions, the mineral may be any mineral particle having cationic surfaces. Examples include iron oxide, kaolin, calcium carbonate, calcium phosphate and/or any of the inorganic pigments listed in Kirk Othmer, Encyclovedia of Chemical Technology, vol. 17, Wiley, New York, pp. 790-793 (1982), which is incorporated herein by reference. Of course, the dispersion may contain other minerals, in addition to those mentioned, and other nonmineral components, as well. The concentration of the mineral in the dispersion is suitably >0 to 80% by weight, preferably 0.01 to 50%, most preferably 0.1 to 30%, and the concentration of the compound of formula (I) or (II) is suitably 0.01 to 800 µg/ml, preferably 0.1 to 300 µg/ml, most preferably 1.0 to 100 µg/ml. Examples of such stabilized dispersions include, for example, paints, cosmetics, boiler water, cooling water, and paper-processing fluids.

The present invention also relates to deterative systems which contain a compound of formula (I) or (II). In addition to the present polyamino acids, the present deterative system may contain the conventional ingredients of deterative systems. Conventional additives of deterative systems are discussed in Kirk-Othmer, Encyclopedia of Chemical Technology, Vol. 22, pp. 332-432 (1983), which is incorporated herein by reference. Thus, the present deterative systems may also contain conventional anionic surfactants, including, e.g., carboxylates, such as soaps, polyalkoxycarboxylates, Nacylsarcosinates, acylated protein hydrolysates, sulfonates, alkylbenzenesulfonates, short-chain alkylarenesulfonates, lignosulfonates,

naphthalenesulfonates, α -olefinsulfonates, petroleum sulfonates, sulfonates with ester, amide or ether linkages, sulfates and sulfated products, alcohol sulfates, ethoxylated and sulfated alcohols, ethoxylated and sulfated
5 alkylphenols, sulfated acids, amides, and esters, sulfated natural oils and fats, and phosphate esters.

The present deterative systems may also contain nonionic surfactants, including polyoxyethylene surfactants (ethoxylates), such as alcohols ethoxylates and alkylphenol
10 ethoxylates, carboxylic acid esters, such as glycerol esters, polyoxyethylene esters, anhydrosorbitol esters, ethoxylated anhydrosorbitol esters, ethoxylated natural fats, oil and waxes, and glycol esters of fatty acids, carboxylic amides, diethanolamine condensates,
15 monoalkanolamine condensates, polyoxyethylene fatty acid amides, and polyalkylene oxide block copolymers, such as poly(oxyethylene-co-oxypropylene) nonionic surfactants.

The present deterative systems may also contain conventional cationic surfactants, including amines, such
20 as oxygen-free amines (e.g., aliphatic mono, di-, and polyamines derived from fatty and resin acids) and oxygen containing amines other than amides (e.g., amine oxides and alkyl amine ethoxylates), 2-alkyl-1-(2-hydroxyethyl)-2-imidazolines, amines with amide linkages, and quaternary
25 ammonium salts.

The present deterative systems may also include conventional amphoteric surfactants, including imidazolium derivatives.

The present deterative systems may be formulated by any
30 conventional method and to include other conventional

additives in addition to the surfactants described above. Thus, the present detergents may include conventional builders such as, phosphates (e.g., $\text{Na}_5\text{P}_3\text{O}_{10}$, $\text{Na}_4\text{P}_2\text{O}_7$, Na_3PO_4 , glassy phosphates and potassium phosphates), sodium
5 carbonate, silicates (e.g., sodium silicates), zeolites (e.g., type A), clays (e.g., kaolin, montmorillonites, and bentonites), nitrilotriacetic acid, alkalies, (e.g., NaOH), and neutral soluble salts (e.g., Na_2SO_4).

The present deterative systems may also contain other
10 conventional organic additives, including: conventional antiredeposition agents, such as carboxymethylcellulose (NaCMC), methylcellulose, hydroxybutylcellulose, hydroxypropyl- and mixed methyl and hydroxylbutyl cellulose ethers; fluorescent whitening agents; bluing agents;
15 bleaching agents, such as $\text{NaBO}_3 \cdot 4\text{H}_2\text{O}$, chlorinated trisodium orthophosphate and chlorinated isocyanurate; foam regulators, such as amine oxides and alkanolamides; and organic sequestering agents, such as EDTA.

The present deterative systems include liquids and
20 powders. The liquid deterative systems may be prepared by metering and mixing the individual ingredients in the proper amounts. The powder deterative systems may be prepared as either spray-dried powders, dry-blended powders, or agglomerated powders by conventional
25 techniques, such as those described in Kirk-Othmer, Encyclopedia of Chemical Technology, Vol. 22, pp. 332-432 (1983).

In the present deterative systems, the compounds of formulae (I) and (II) are suitably present in an amount of
30 0.1 to 50.0 wt.%, preferably 0.1 to 30 wt.%, most preferably 1 to 10 wt.%.

The present invention also relates to cosmetics, such as shampoos and body soaps, which contain the compounds of formula (I) or (II). In addition to the compounds of formulae (I) and (II), the present shampoos may contain other conventional additives and ingredients. Conventional additives and ingredients for shampoos are discussed in Kirk-Othmer, Encyclopedia of Chemical Technology, Vol. 7, pp. 163-168 (1979), which is incorporated herein by reference. Thus, the present shampoos may contain:

- 10 detergents, such as fatty alcohol sulfates, ether sulfates, sarcosinates, and alkanolamides; soft soaps; sulfonated oils, such as sulfonated castor oil and sulfonated olive oil; preservatives; coloring agents; perfumes; anionic surfactants; amphoteric surfactants, such as imidazoline,
- 15 betaine, and sulfobetaine surfactants; antidandruff agents, such as coal tar, quaternary ammonium compounds, resorcinol, salicylic acid, selenium sulfide, sulfur, undecylenic acid and derivatives, and zinc pyrithione; foam builders; conditioning agents; opacifying agents;
- 20 sequestering agents, such as citric acid, tartaric acid, and salts of EDTA; and viscosity builders.

In the present shampoos, the compounds of formulae (I) and (II) are suitably present in an amount of 0.1 to 50 wt.%, preferably 0.1 to 30 wt.%, most preferably 1 to 10 wt.%.
25 wt.%.

The present invention also relates to body and facial soaps which contain a compound of formula (I) or (II). The present soaps may be prepared according to conventional methods as described in Kirk-Othmer, Encyclopedia of
30 Chemical Technology, Vol. 21, pp. 162-181 (1983), which is incorporated herein by reference. Thus, the present soaps may contain, in addition to the compounds of formulae (I)

and (II), any conventional metal salt of a long-chain monocarboxylic acid and conventional additives, including: antibacterial agents, such as 3,4,4'-trichlorocarbanilide and 2-hydroxy2',4,4'-trichlorodiphenyl ether; superfatting
5 agents, such as unsaponified oils, fatty acids, or lanolin, mineral oil, fatty esters, and fatty alcohols; transparency agents, such as alcohol, sugar, and glycerin; abrasives, such as pumice; and builders, such as sodium silicate, sodium carbonate, and trisodium phosphate.

10 The present soaps may be in the form of a bar, a powder, or a liquid. The compounds of formulae (I) and (II) are suitably present in an amount of 0.1 to 50 wt.%, preferably 0.1 to 30 wt.%, most preferably 1 to 10 wt.%.

Other features of the invention will become apparent
15 in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

Examples

Synthesis of the Polypeptides

20 An automated, solid-phase synthesizer (Applied Biosystems, Model 430A) was used to prepare peptides of precisely known sequence and molecular size. The t-Boc strategy of terminal amine protection was used with aspartic acid supplied as t-Boc-L-aspartic acid with beta
25 carboxyl protection by O-benzyl linkage. Similarly, serine was supplied as t-Boc-L-serine-O-benzyl.

In all cases, coupling efficiency of each residue was checked by automated sampling of peptide resin for

measurement of unreacted free amine by the ninhydrin method (Sarin, V.K., et al., Anal. Bioch. Vol. 117, pp. 147-157 (1981)). Coupling efficiencies routinely were greater than 99% per cycle of synthesis.

- 5 The carboxy terminal amino acid was preloaded via an organic linker (PAM, 4-oxymethyl phenylacetamidomethyl) covalently attached to an insoluble polystyrene resin cross-linked with divinyl benzene.

10 In this preferred embodiment, the C-terminus of the polypeptides was aspartate and the C-terminal region polyanionic, with hydrophobic residues added to the polypeptides on the N-terminus. The reason for this orientation is that the aspartate-PAM linkage is easier to cleave at the end of the synthesis as compared to
15 hydrophobic amino acid-PAM linkages, resulting in greater yields. It is not likely that the positioning of the polyanionic or hydrophobic regions at the C- vs. the N-terminus matters with regard to activity.

20 Following synthesis, peptide-resin was repeatedly washed with methanol then dried and weighed. Then peptides were cleaved from the resin using a modification of the trifluoromethanesulfonic acid (TFMSA) procedure, with precautions taken to prevent aspartimide formation (Bergot, J.B., et al., Applied Biosystems Bulletin (1986)). For 100
25 mg samples, peptide-resins in a scintillation vial were treated for 10 minutes with 150 μ l of anisole to swell the resin, making it more accessible for reaction. Then 1.0 ml of neat trifluoroacetic acid (TFA) was added with magnetic stirring and allowed to react for 10 minutes. Next, 100 μ l
30 of concentrated TFMSA (Aldrich Chemical Co.) were added with cooling using an ice bath, followed by cleavage of the

peptide from the resin at room temperature for 30 minutes. For cleavage of other amounts of peptide-resin, the amounts of reagents used were changed proportionally.

Following cleavage, 20 ml of methyl butyl ether (MBE) (Aldrich) were added to the vial to ensure precipitation of the peptide, which already was relatively insoluble in the acidic reaction medium due to the acidic nature of the peptides. After stirring for 1-2 minutes, the entire slurry was passed through a 4.25 cm glass fiber filter (Fisher G4) using a filter funnel and vacuum pump at 15 psi. This removed the TFA, TFMSA, anisole, and any soluble reaction products, leaving the cleaved peptide and resin on the filter.

Extraction of Metal Salts of the Peptides

After washing on the filter with 100 ml of MBE, the acid form of the peptides was converted into a soluble sodium salt by extraction into a clean, dry flask with 10 ml of Na_2CO_3 (0.02 M, pH 10.2), using 5 successive rinses of 2 ml, with at least 1 minute extraction on the filter prior to applying the vacuum each time. Conversion of the peptides to other metal adducts such as Zn or Al forms may be accomplished by adding an excess of soluble salts of the metals; for example, ZnCl_2 or AlCl_3 , to the Na_2CO_3 solution used for the extraction.

25 Purification of the Peptides

Upon extraction, the filtrate containing the solubilized peptides had pH values >5. The filtrate was then dialyzed twice with stirring against 2 liters of distilled water for 2 hours using dialysis tubing

(Spectrapor, nominal MW cutoff of 1000 daltons). The dialysate was frozen and lyophilized, yielding white flakes or powders. The average yield of the peptides was 40%.

Following isolation, purity of the peptides was
5 checked by high performance liquid chromatography (Varian 5500 LC) using gel permeation columns designed for separations of peptides (Toya Soda 2000 SW and 3000 PWXL). Single, sharp peaks at the appropriate MW's were obtained.

Because the peptides were isolated partially as sodium
10 salts, the sodium content was determined by atomic absorption (Perkin Elmer model 360). Sodium levels typically were less than 5% by weight. Amounts of peptides reported are corrected for sodium content. Concentrations of peptides in aqueous stock solution were based on
15 lyophilized dry weight but were also checked by comparison of UV spectra.

Thermal Peptide Synthesis

Peptides of approximately known sequence and size were made by thermal polymerization of amino acids (Fox, S.W. and K. Harada, "Thermal polycondensation of alpha-amino acids" in A Laboratory Manual of Analytical Methods of Protein Chemistry, Vol. 4, P. Alexander and H.P. Lundgren (eds.), 1966, pp. 127-151). For example, L-aspartic acid (500 g) was placed in a two-liter, round-bottom reaction
25 vessel, originally designed as the evaporator vessel in a rotary evaporator apparatus. The reaction vessel was partially submerged in cooking oil in a deep-fryer set at 190°C ($\pm 2^\circ\text{C}$). The reaction vessel was coupled by ground glass fitting to a condenser vessel, which in turn was
30 fitted to a rotator shaft driven by a rheostated electric

motor. The fittings were sealed with tape and fastened with hose clamps. A stream of nitrogen was continuously purged into the condenser vessel to eliminate O₂ and the possibility of charring. The reaction was allowed to
5 continue for up to 24 hours at which time no further visible evolution of water vapor was observed. The water is produced as a result of the dehydration reaction of peptide bond formation and serves as a good indicator of the progress of the reaction.

10 Polyaspartate molecules of approximately 5000 daltons (determined by gel permeation) were produced. They were purified by dissolving at pH 6 in water followed by dialysis to remove unreacted aspartic acid, although the bulk product is also usable without further purification.

15 Polyanionic/hydrophobic peptides of approximately-known sequence and size may also be made by conventional thermal polymerization of the polyanionic region and the hydrophobic regions separately using R-group protected amino acids (Melius, P. and J.Y.P. Sheng, Bioorg. Chem.,
20 Vol. 4, pp. 385 (1975)). Next, the polyanionic and hydrophobic regions can be linked thermally, followed by deprotection of the R-groups using cleavage reagents. There is some evidence to suggest that a polyanionic/hydrophobic peptide may assemble naturally
25 under thermal polymerization conditions, without the need for separate synthesis followed by attachment of the two regions (Phillips, R.D. and P. Melius, Int. J. Peptide Protein Res., Vol. 6, pp. 309-319 (1974))).

Phosphorylation of Peptides

Serine residues attached at either the N-terminus or the C-terminus were phosphorylated via the method of Neuhaus and Korkes (1958). Phosphorus oxychloride, POCl_3 , was added as 117 ml (1.25 moles) to 45 ml (2.5 moles) of water. This solution was stirred for one hour, allowing formation of monochlorophosphate (ClH_2PO_3). Next, amounts up to 0.25 moles of peptides were added with stirring and occasional heating at 60°C for two hours. The reaction was ended by dropwise addition of 18 ml (1 mole) of H_2O to degrade any unreacted monochlorophosphate to orthophosphate. Any polyphosphates that may have formed during the reaction were destroyed by addition of 75 ml of 1N HCl and heating in a boiling water bath for at least 20 minutes. Upon cooling, peptides were crystallized in 95 percent ethanol and methyl butyl ether at 3°C overnight. Crystals were washed repeatedly with ethanol. The extent of phosphorylation of peptides was monitored spectrophotometrically by formation of the phosphomolybdate complex (Eisenreich et al., Environmental Letters, Vol. 9, pp. 43-53 (1975)).

Industrial Polymers

Industrial polymers were acquired from water-treatment chemical companies. A 4-5 kD polyacrylate (Buckman Chemical Co.) is a widely used commercial dispersant. A 5-8 kD terpolymer of acrylic acid, acrylamide, and acrylamide-alkyl sulfonate (Nalco Chemical Co.) is representative of a new generation of commercial dispersants.

Mineral Particles

Kaolin (an aluminum silicate) was chosen for study to represent dispersions of clay or soil particles. Iron oxide is a common mineral that requires dispersion in boiler and cooling water. Calcium hydroxyapatite and carbonate are also common problem minerals encountered in water treatment. In addition, calcium hydroxyapatite is a major constituent of dental tartar and dispersion of both calcium carbonate and kaolin is used in providing fillers and pigments in paper. Thus, the mineral particles studied were chosen to represent a wide variety of dispersion applications.

Example 1. Kaolin Dispersion

500 mg kaolin (Sigma; particle size 0.1 - 4.0 μm) was weighed and placed in a 600 ml beaker. Distilled water was added to the 400 ml mark. 1 ml of 0.5 M $\text{MgCl}_2 \cdot \text{H}_2\text{O}$; 1.8 ml of 1.0 M $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; and 4.5 ml of 0.4 M NaHCO_3 were added to the solution in the order presented. This added ionic strength, simulating hard water. Mg^{+2} helped to prevent CaCO_3 precipitation in solution or at the surface of the kaolin. Microliter amounts of 1 N NaOH were added to bring the pH to 8.50. Approximately 90 ml of distilled H_2O were added to bring the final volume to 500 mls, resulting in a concentration of 1.0 mM MgCl_2 , 3.6 mM CaCl_2 , and 3.6 mM NaHCO_3 . 50 ml aliquots were placed in 2 oz. (60 ml) vials. The vials (9) were placed on a multiple magnetic stirring plate in a recirculating water bath at 20°C. Peptide or polymer was added at a concentration of 10 $\mu\text{g}/\text{ml}$, and the suspensions were stirred for one hour. While the vials were still being stirred, an initial sample (3 mls) was taken at 1.5 cm below the surface and placed in a 4 ml

disposable cuvette. The samples were gently agitated and turbidity was measured by absorbance using a spectrophotometer (Perkin Elmer lambda 4) at 500 nm. The stirring was stopped immediately after the initial
 5 sampling. After 30 minutes, a final sample was taken at 1.5 cm below the surface. The amount of absorbance was measured and recorded. The results are shown in Figure 1 and Table 1.

Table 1. Kaolin Dispersion

10	Sample	Absorbance \pm S.D.	n	Amount of Dispersant (μ g/ml)
	Control	0.2943 \pm 0.0232	18	--
	HO-Asp ₃₀ Ala ₄ -H	0.4208 \pm 0.0279	6	10
	H-PSer ₇ Asp ₁₅ Ala ₄ -OH	0.3962 \pm 0.0354	6	10
	HO-Asp ₂₀ Ala ₂ -H	0.3883 \pm 0.0031	3	10
15	HO-Asp ₂₀ Ala ₂₀ -OH	0.3397 \pm 0.0273	6	10
	Polyaspartate	0.3192 \pm 0.0215	9	10

Absorbance @ 500 nm after settling for 30 minutes.

Example 2. Iron oxide Dispersion

Particulate iron oxide dispersion was measured with
 20 calcium present because divalent ions such as calcium interfere with the activity of conventional polymers. Samples that did not contain calcium served as controls.

Six 1000 ml beakers were filled with 950 ml of distilled water. One mg of polymer or peptide and 9 ml of
 25 0.4 M NaHCO₃ (Fisher) were added to all six beakers. Next,

3.6 ml of 1.0 M CaCl_2 (Fisher) were added to only three beakers. All beakers were titrated to pH 8.5 with μl amounts of 1 N NaOH or 1 N HCl. The solutions were brought to final volume in 1000 ml volumetric flasks. Finally, a
 5 slurry was made in the beakers with 100 mg Fe_2O_3 (Fisher) with small amounts of distilled water and the appropriate volumetric solutions. All beakers were placed on a multiple magnetic stir plate submerged in a recirculating bath (VWR model 1155) maintained at 20°C. Aliquots of 3 ml
 10 were taken at 0, 1, 2, and 5 hours at a depth of 1 cm and placed in a 4 ml disposable cuvette. Each sample was resuspended and read at 500 nm using a spectrophotometer (Perkin Elmer lambda 4). Elevated absorbance versus time
 15 stabilizing activity. The results are shown in Table 2 and Figures 2-4.

Table 2. Iron Oxide Dispersion

Sample	Absorbance \pm S.D.	n	Dose ($\mu\text{g/ml}$)
HO-Asp ₂₀ Ala ₅ -H	0.3653 \pm 0.0403	6	1.0
HO-Asp ₂₀ Ala ₂₀ -H	0.3162 \pm 0.0442	6	1.0
HO-Asp ₂₀ Ala ₅ -H	0.3147 \pm 0.0482	3	1.0
HO-PSer ₂ Asp ₁₅ Ala ₅ -OH	0.2888 \pm 0.0303	6	1.0
PolyAsp(thermal)	0.1667 \pm 0.0226	6	1.0
Polyacryalte	0.1220 \pm 0.0345	6	1.0

Absorbance @ 500 nm after 5 hours.

Example 3. Calcium Phosphate

First, 1 g of hydroxyapatite (Aldrich calcium phosphate tribasic) was suspended in a 1 liter solution of 1 mM NaHCO₃ (Fisher) in distilled water. The solution was adjusted to pH 8.0. After vigorous shaking, a 3.0 ml aliquot was pipetted from the center of the stock solution, and placed in a 4.0 ml glass cuvette, resuspended, and placed in a water-jacketed cell holder at 20°C. The crystals were allowed to settle in the cuvette for 20 minutes. The settling was continuously monitored using a spectrophotometer (Perkin Elmer lambda 4) at 500 nm.

After the initial and final absorbances were recorded, 0.2 µg/ml of the polymer or peptide was added to the sample. The sample was resuspended and allowed to settle for 20 minutes in the cuvette. The difference between the control slope and the experimental slope was used to determine dispersion activity. A slower settling rate is characteristic of better dispersion activity. The results are shown in Figure 5 and in Table 3.

Sample	Slope ^a	S.D.	n	Amount of Dispersant (µg/ml)
Control	0.0098 ±	0.0006	34	--
PolyAsp(thermal)	0.0057 ±	0.0002	6	0.2
Polyacrylate	0.0056 ±	0.0012	5	0.2
Terpolymer	0.0052 ±	0.0002	5	0.2
HO-Asp ₂₀ OAla ₈ -H	0.0046 ±	0.0006	4	0.2

^a absorbance units/minute.

Example 4. Calcium Carbonate

Fifty mg of calcium carbonate were weighed and placed in each of twelve 2 oz (60 ml) vials. Fifty ml of H₂O were added to each vial. Each vial was placed on a multiple
5 magnetic stir plate submerged in a recirculating water bath maintained at 20°C. One hundred μ l of 0.5 M MgCl₂ and 180 μ l of 1.0 M CaCl₂ were added to each slurry to add hardness. Dissolved CaCO₃ brought the pH above 8.0. Peptide or
polymer was added to each of three vials at concentrations
10 of 0, 1, 2, and 5 μ g/ml. The set of vials that had no polymer or peptide added served as a control. Aliquots of 3 mls were taken at 0, 5, and 20 hours at a depth of 1.5 cm and placed in a 4 ml disposable cuvette. Each sample was
resuspended, and the absorbance was read at 500 nm in a
15 spectrophotometer. Increased dispersion activity was measured by an increase in absorbance.

Table 4. Calcium Carbonate Dispersion After 20 Hours
in the Presence of Peptide and Polymer Dispersants

Dispersant	Dose ($\mu\text{g/ml}$)	Mean Absorbance \pm S.D.	n
Control	-	0.376 ± 0.043	32
Polyacrylate	1	0.438 ± 0.043	3
	2	0.482 ± 0.043	3
	5	0.490 ± 0.030	3
CX-957 (sulfonated terpolymer)	2	0.486 ± 0.026	6
	5	0.510 ± 0.018	5
Polyaspartate (thermal)	1	0.433 ± 0.027	6
	2	0.472 ± 0.016	5
	5	0.417 ± 0.024	6
HO-Asp ₂₀ -Ala ₅ -H	1	0.467 ± 0.004	3
	2	0.509 ± 0.008	3
	5	0.532 ± 0.026	3
HO-Asp ₂₀ -Ala ₅ -H	1	0.444 ± 0.043	9
	2	0.492 ± 0.058	9
	5	0.502 ± 0.022	8
HO-Asp ₈ -Asp ₁₅ -P _{Ser} ₂ -H	1	0.493 ± 0.027	6
	2	0.532 ± 0.031	6
	5	0.497 ± 0.064	6

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

Claims

1. A method of stabilizing an aqueous mineral suspension, comprising adding at least one compound having formula (I) or (II) to said suspension:

5 poly (X)_n poly (Y)_m

where each X independently is aspartic acid, glutamic acid, phosphoserine, phosphohomoserine, phosphotyrosine, or phosphothreonine,

each Y independently is alanine, leucine, isoleucine,
10 valine, glycine or other nonpolar, amino acid residues,

n is 2 to 60,

m is 2 to 60, and

n + m is ≥ 5 ,

and wherein poly (X)_n may contain up to 10% of the Y
15 residues and poly (Y)_m may contain up to 10% of the X residues, and salts thereof; and

poly (X')_n poly (Y')_m (II)

where each X' independently is aspartate, glutamate, glutamine, asparagine, or anionic derivatives of
20 these amino acids, or phosphoserine,

each Y' independently is a phosphorylated amino acid
such

as phosphoserine, phosphohomoserine,
phosphotyrosine, phosphothreonine,
phosphoglutamine, phosphoasparagine or mixtures
of these residues,

- 5 a is 2 to 150,

 b is 1 to 3, and

 a + b is ≥ 5 , and

salts of these peptides; wherein said suspension
contains at least one mineral.

- 10 2. A stabilized aqueous mineral suspension,
comprising at least one compound having formula (I) or
(II):

poly (X)_n poly (Y)_m (I)

- where each X independently is aspartic acid, glutamic
15 acid,

phosphoserine, phosphohomoserine,
phosphotyrosine, or phosphothreonine,

- each Y independently is alanine, leucine, isoleucine,
valine, glycine or other nonpolar, amino acid
20 residues,

n is 2 to 60,

m is 2 to 60, and

$n + m$ is ≥ 5 ,

and wherein poly (X)_n may contain up to 10% of the Y residues and poly (Y)_m may contain up to 10% of the X residues, and salts thereof; and

5 poly (X'), poly (Y'),

where each X' independently is aspartate, glutamate, glutamine, asparagine, or anionic derivatives of these amino acids, or phosphoserine,

each Y' independently is a phosphorylated amino acid
10 such

as phosphoserine, phosphohomoserine,
phosphotyrosine, phosphothreonine,
phosphoglutamine, phosphoasparagine or mixtures
of these residues,

15 a is 2 to 150,

b is 1 to 3, and

a + b is ≥ 5 , and

salts of these peptides; wherein said suspension
contains at least one mineral.

20 3. The suspension of Claim 2, wherein said suspension
is a paint.

4. A deterrent system, comprising (a) at least one
compound having formula (I) or (II):

poly (X)_n poly (Y)_m

where each X independently is aspartic acid, glutamic acid, phosphoserine, phosphohomoserine, phosphotyrosine, or phosphothreonine,

5 each Y independently is alanine, leucine, isoleucine, valine, glycine or other nonpolar, amino acid residues,

n is 2 to 60,

m is 2 to 60, and

10 n + m is ≥ 5 ,

and wherein poly (X)_n may contain up to 10% of the Y residues and poly (Y)_m may contain up to 10% of the X residues, and salts thereof; and

poly (X')_a poly (Y')_b (II)

15 where each X' independently is aspartate, glutamate, glutamine, asparagine, or anionic derivatives of these amino acids, or phosphoserine,

each Y' independently is a phosphorylated amino acid such as phosphoserine, phosphohomoserine,
20 phosphotyrosine, phosphothreonine, phosphoglutamine, phosphoasparagine or mixtures of these residues,

a is 2 to 150,

b is 1 to 3, and

a + b is ≥ 5 , and

salts of these peptides, and (b) one member selected from the group consisting of surfactants, builders, and
5 water.

5. A cosmetic composition suitable for application to human hair and aqueous rinsing therefrom, comprising a compound which is effective for the cleansing of hair and at least one compound having formula (I) or (II):

10 poly (X)_n poly (Y)_m

where each X independently is aspartic acid, glutamic acid, phosphoserine, phosphohomoserine, phosphotyrosine, or phosphothreonine,

15 each Y independently is alanine, leucine, isoleucine, valine, glycine or other nonpolar, amino acid residues,

n is 2 to 60,

m is 2 to 60, and

n + m is ≥ 5 ,

20 and wherein poly (X)_n may contain up to 10% of the Y residues and poly (Y)_m may contain up to 10% of the X residues, and salts thereof; and

poly (X')_n poly (Y')_m

(II)

where each X' independently is aspartate, glutamate,
glutamine, asparagine, or anionic derivatives of
these amino acids, or phosphoserine,

each Y' independently is a phosphorylated amino acid such
5 as phosphoserine, phosphohomoserine,
phosphotyrosine, phosphothreonine,
phosphoglutamine, phosphoasparagine or mixtures
of these residues,

a is 2 to 150,

10 b is 1 to 3, and

a + b is ≥ 5 , and

salts of these peptides.

6. A cosmetic composition suitable for application to
human skin, comprising a compound effective for cleansing
15 human skin and at least one compound having formula (I) or
(II):

poly (X)_n poly (Y)_m (I)

where each X independently is aspartic acid, glutamic
acid, phosphoserine, phosphohomoserine,
20 phosphotyrosine, or phosphothreonine,

each Y independently is alanine, leucine, isoleucine,
valine, glycine or other nonpolar, amino acid
residues,

n is 2 to 60,

m is 2 to 60, and

n + m is ≥ 5 ,

and wherein poly (X)_m may contain up to 10% of the Y residues and poly (Y)_n may contain up to 10% of the X residues, and salts thereof; and

poly (X'), poly (Y'), (II)

where each X' independently is aspartate, glutamate, glutamine, asparagine, or anionic derivatives of these amino acids, or phosphoserine,

10 each Y' independently is a phosphorylated amino acid such as phosphoserine, phosphohomoserine, phosphotyrosine, phosphothreonine, phosphoglutamine, phosphoasparagine or mixtures of these residues,


15 a is 2 to 150,

b is 1 to 3, and

a + b is ≥ 5 , and

salts of these peptides.

1/5

*FIG. 1*

SUBSTITUTE SHEET

2/5




FIG. 2

SUBSTITUTE SHEET

3/5




FIG. 3

SUBSTITUTE SHEET

4/5




FIG. 4

SUBSTITUTE SHEET

5/5




FIG. 5

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/07557

I. CLASSIFICATION OF SUBJECT MATTER (In several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): C08L 53/00 U.S. CL. 424/689		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	424/689	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y, P	US, A, 5,051,401 (SIKES) 24 SEPTEMBER 1991 See entire document.	1-6
Y	US, A, 4,678,840 (FONG ET. AL.) 07 JULY 1987 See entire document.	1-6
Y	US, A, 4,735,797 (GROLIER ET. AL.) 05 APRIL 1988 See entire document.	1-6
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>[*] Special categories of cited documents: ¹⁴</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
29 April 1992		11 JUN 1992
International Searching Authority		Signature of Authorized Person
• ISA/US		David J. Colucci